Pulmonary arterial hypertension (PAH) is characterized by remodeling and narrowing of the pulmonary vasculature which results in elevations of pulmonary arterial pressures. Here, we conducted a genome-wide association study (GWAS) using the UK Biobank, analyzing the genomes of 493 individuals diagnosed with primary pulmonary hypertension, based on ICD-10 coding, compared to 24,650 age, sex, and ancestry-matched controls in a 1:50 case-control design. Genetic variants were analyzed by Plink's firth logistic regression and assessed for association with primary pulmonary hypertension. We identified three linked variants in the gene, which encodes a protooncogene that has been garnering interest as a potential therapeutic target for PAH, that were associated with PAH with genome wide significance, one (rs192449585) of which lies in the promoter region of the gene. We also identified 15 linked variants in the gene. These results provide genetic evidence supporting the role of inhibitors as a potential therapeutic option for PAH.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10121214PMC
http://dx.doi.org/10.3389/fddsv.2023.1127736DOI Listing

Publication Analysis

Top Keywords

pulmonary arterial
12
genetic variants
8
arterial hypertension
8
primary pulmonary
8
pulmonary hypertension
8
linked variants
8
variants gene
8
potential therapeutic
8
pulmonary
6
identification novel
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!